Safeway announces final distribution ratio for Blackhawk Network Holdings stock
PLEASANTON, Calif. — Safeway on Tuesday announced the final distribution ratio for the previously announced special stock dividend to its stockholders of all of the shares of Class B common stock of Blackhawk Network Holdings held by Safeway.
Safeway stockholders will receive 0.164291 of a share of Blackhawk Class B common stock for every share of Safeway common stock held as of the close of business on April 3, 2014.
The distribution will be made on April 14, 2014 in the form of a pro rata distribution of all of the 37.8 million shares of Class B common stock of Blackhawk owned by Safeway to all Safeway stockholders of record on the record date. No fractional shares of Blackhawk Class B common stock will be distributed. Instead, Safeway stockholders will receive cash in lieu of any fraction of a share of Blackhawk Class B common stock that they otherwise would have received.
CVS Caremark finalizes previously announced settlement with SEC
WOONSOCKET, R.I. — CVS Caremark announced on Tuesday that it has finalized with the Securities and Exchange Commission a settlement that was previously announced in August 2013.
The settlement was entered into on a "no admit or deny basis" and will not require CVS Caremark to restate its earnings for any reporting period. The company stated that the matter is now fully resolved.
As previously announced last year when the company disclosed that it had reached an agreement in principle with the staff of the SEC, the settlement relates to events that occurred in the third and fourth quarters of 2009, including certain public disclosures made by the company and certain aspects of the purchase accounting adjustment related to the October 2008 Longs Drug Stores acquisition.
L’Oréal Paris, Melanoma Research Alliance launch campaign to fight melanoma
NEW YORK — L’Oréal Paris and the Melanoma Research Alliance, a private funder of melanoma research, have announced the launch of the “It’s THAT Worth It” campaign, a public health call-to-action that urges women of all skin tones to prevent melanoma by using sunscreen and to help save lives by supporting melanoma research for a cure.
As part of the three-year partnership, L’Oréal Paris is donating $750,000 to MRA to help find a cure through the funding of the new L’Oréal Paris-MRA Team Science Award. The donation will fund research exploring the role of 16 variant genes as co-drivers in melanoma susceptibility, development and progression.
“The Melanoma Research Alliance is an incredible organization that has made significant strides in funding melanoma research and advancing treatment. We are very proud to partner with MRA to help educate people on the importance of using sunscreen as the first line of defense against melanoma and to drive awareness around this disease,” stated Karen Fondu, president of L’Oréal Paris. “Through this collaboration, our hope is to drastically reduce the growing incidence of melanoma in this country, especially among young women, and to help every person realize that wearing sunscreen protects their beauty and their life because we are all worth it.”
Celebrity broadcast and print PSAs are the first phase in a series of initiatives designed to rally the public to combat melanoma. The PSAs drive the public to ItsTHATworthit.org to join Thunderclap, a worldwide crowd-sourcing tool that amplifies a collective message. By signing up for the It’s THAT Worth It Thunderclap from now through May 20 at 5 p.m. EDT, people can lend their reach to the cause, and send a synchronized message through social media, telling the world that they are committed to stopping melanoma through prevention and research. As a thank you, L‘Oréal Paris will make a donation to MRA of $1 for each supporter who signs up for the Thunderclap and $1 for each L’Oréal Paris Advanced Suncare product sold in the United States — up to $250,000 in 2014.
Melanoma Quick Facts
- Melanoma of the skin is the deadliest form of skin cancer, responsible for 80% of skin cancer deaths;
- Melanoma is the fifth most common cancer diagnosed in the United States;
- The incidence of melanoma has tripled in the last 30 years, making it one of the fastest growing cancers;
- Melanoma is the third most commonly diagnosed cancer among adolescents and young adults aged 15 years to 39 years in the United States; and
- Very early stage (localized Stage 0 or 1) melanoma is greater than 90% curable with surgery, while patients with disseminated Stage IV melanoma have a median life expectancy of less than one year.